172 related articles for article (PubMed ID: 12939207)
1. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R;
Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
3. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
4. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
5. Effect of Valsartan on hospitalization: results from Val-HeFT.
Carson P; Tognoni G; Cohn JN
J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565
[TBL] [Abstract][Full Text] [Related]
6. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
8. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
De Tommasi E; Iacoviello M; Romito R; Ceconi C; Guida P; Massari F; Francolini G; Bertocchi F; Ferrari R; Rizzon P; Pitzalis MV
Am Heart J; 2003 Nov; 146(5):E17. PubMed ID: 14597946
[TBL] [Abstract][Full Text] [Related]
10. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
11. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
12. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
13. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L
Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110
[TBL] [Abstract][Full Text] [Related]
14. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Anand IS; Latini R; Florea VG; Kuskowski MA; Rector T; Masson S; Signorini S; Mocarelli P; Hester A; Glazer R; Cohn JN;
Circulation; 2005 Sep; 112(10):1428-34. PubMed ID: 16129801
[TBL] [Abstract][Full Text] [Related]
16. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
17. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
18. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
[TBL] [Abstract][Full Text] [Related]
19. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Latini R; Masson S; Anand I; Judd D; Maggioni AP; Chiang YT; Bevilacqua M; Salio M; Cardano P; Dunselman PH; Holwerda NJ; Tognoni G; Cohn JN;
Circulation; 2002 Nov; 106(19):2454-8. PubMed ID: 12417542
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
